HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer

Detalles Bibliográficos
Autores principales: Nakamura, Yoshiaki, Sawada, Kentaro, Fujii, Satoshi, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615873/
https://www.ncbi.nlm.nih.gov/pubmed/31354963
http://dx.doi.org/10.1136/esmoopen-2019-000530
_version_ 1783433417134702592
author Nakamura, Yoshiaki
Sawada, Kentaro
Fujii, Satoshi
Yoshino, Takayuki
author_facet Nakamura, Yoshiaki
Sawada, Kentaro
Fujii, Satoshi
Yoshino, Takayuki
author_sort Nakamura, Yoshiaki
collection PubMed
description
format Online
Article
Text
id pubmed-6615873
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-66158732019-07-28 HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer Nakamura, Yoshiaki Sawada, Kentaro Fujii, Satoshi Yoshino, Takayuki ESMO Open Correspondence BMJ Publishing Group 2019-07-08 /pmc/articles/PMC6615873/ /pubmed/31354963 http://dx.doi.org/10.1136/esmoopen-2019-000530 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Correspondence
Nakamura, Yoshiaki
Sawada, Kentaro
Fujii, Satoshi
Yoshino, Takayuki
HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer
title HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer
title_full HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer
title_fullStr HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer
title_full_unstemmed HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer
title_short HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer
title_sort her2-targeted therapy should be shifted towards an earlier line for patients with anti-egfr-therapy naïve, her2-amplified metastatic colorectal cancer
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615873/
https://www.ncbi.nlm.nih.gov/pubmed/31354963
http://dx.doi.org/10.1136/esmoopen-2019-000530
work_keys_str_mv AT nakamurayoshiaki her2targetedtherapyshouldbeshiftedtowardsanearlierlineforpatientswithantiegfrtherapynaiveher2amplifiedmetastaticcolorectalcancer
AT sawadakentaro her2targetedtherapyshouldbeshiftedtowardsanearlierlineforpatientswithantiegfrtherapynaiveher2amplifiedmetastaticcolorectalcancer
AT fujiisatoshi her2targetedtherapyshouldbeshiftedtowardsanearlierlineforpatientswithantiegfrtherapynaiveher2amplifiedmetastaticcolorectalcancer
AT yoshinotakayuki her2targetedtherapyshouldbeshiftedtowardsanearlierlineforpatientswithantiegfrtherapynaiveher2amplifiedmetastaticcolorectalcancer

Ejemplares similares